Genetic Associations with Valvular Calcification and Aortic Stenosis: The CHARGE Consortium

This genome-wide association study from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium examined the genetic determinants of aortic valve calcification in 6,942 participants of European ancestry across four population-based cohorts, with replication in additional samples.

The study identified a highly significant association between the LPA gene locus — which encodes apolipoprotein(a), the defining component of Lp(a) — and both aortic valve calcification and clinical aortic stenosis. The top variant (rs10455872) reached genome-wide significance (p=2.9×10⁻¹²) and was associated with substantially higher Lp(a) concentrations, aortic valve calcification, and incident aortic stenosis across multiple cohorts. Each copy of the risk allele increased Lp(a) levels and aortic valve calcification scores.

This GWAS established Lp(a) as a genetically validated causal risk factor for aortic valve calcification and aortic stenosis — not merely an associated biomarker. The genetic evidence for causality is particularly powerful: because LPA variants are randomly allocated at conception (not influenced by lifestyle, diet, or reverse causation), the association between LPA genotype and aortic valve disease provides near-Mendelian evidence that Lp(a) itself drives the valvular pathology.

The mechanistic pathway involves Lp(a)‘s oxidized phospholipid cargo activating inflammatory and pro-calcification signaling in valvular interstitial cells — the same OxPL-driven inflammation that promotes coronary atherosclerosis. Aortic stenosis and coronary calcification share a common upstream driver in Lp(a).

We rate the evidence strong. A landmark GWAS establishing LPA/Lp(a) as a genetically validated causal risk factor for aortic valve calcification and aortic stenosis — one of the most important papers in the Lp(a) field, extending its relevance from coronary artery disease to structural heart disease.